ReviewFrontiers in endocrinology2026
Ectopic lipid deposition in kidney diseases: mechanisms in specific cell types and therapeutic strategies.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elucidating the therapeutic mechanisms of quercetin in hepatic fibrosis: an integrated metabolomic and transcriptomic analysis.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney diseases represent a major global health burden and arise from complex interactions among multiple cellular and molecular processes. Ectopic lipid deposition (ELD), defined as the accumulation of excess lipids in non-adipose tissues when lipid supply exceeds adipose storage capacity, has emerged as a key contributor to the initiation and progression of renal injury. ELD occurs across multiple renal cell types, including proximal tubular epithelial cells, podocytes, mesangial cells, glomerular endothelial cells, as well as interstitial fibroblasts and macrophages. Owing to differences in metabolic profiles and lipid-handling capacity, these cells exhibit distinct susceptibilities and pathological responses to lipid accumulation. This review summarizes the major sources and underlying mechanisms of renal ELD, with particular emphasis on cell-specific injury pathways driven by different lipid subtypes. It further discusses how these divergent responses collectively contribute to renal dysfunction and structural damage. We also outline current approaches for the clinical assessment and diagnosis of renal ELD, and highlight the relevance of age stratification in improving diagnostic precision. Recent advances in therapeutic strategies targeting renal ELD are also reviewed, including evidence from diabetic kidney disease, obesity-related kidney disease, acute kidney injury, and Alport syndrome. Overall, this review provides a systematic overview of the molecular mechanisms and therapeutic implications of ELD in kidney diseases from a cell-specific perspective, and highlights its potential as a target for improved prevention and treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.